6533b872fe1ef96bd12d37c7

RESEARCH PRODUCT

Thymosin α1 and α-Inteferon with Cisplatin and Etoposide in Advanced Non-Small-Cell Lung Cancer: A Phase II Study

Patrizia ViciLuigi Di LauroGiovanni BonsignoreEnrico GaraciM. D'aprileMassimo LopezMarina Della GiuliaCartesio Favalli

subject

CisplatinChemotherapybusiness.industrymedicine.medical_treatmentCancerLewis lung carcinomamedicine.diseaseInterferonmedicineCancer researchBiological response modifiersbusinessLung cancerEtoposidemedicine.drug

description

In recent years, biological response modifiers (BRMs) have emerged as an important new class of agents for treating cancer. Agents such as interferon (IFN) and interleukin 2 (IL-2) have been reported to induce significant tumor regression in various types of cancer usually resistant to chemotherapy (1,12), but their use in non-small-cell lung cancer (NSCLC) has received little attention.

yearjournalcountryeditionlanguage
1993-01-01
https://doi.org/10.1007/978-1-4615-2964-4_17